Related Experiment Video

Updated: Jun 19, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

The variant methylenetetrahydrofolate reductase c.1298A>C (p.E429A) is associated with multiple sclerosis in a German

L Klotz1, M Farkas, N Bain

  • 1Department of Neurology, University Bonn, Bonn, Germany.

Neuroscience Letters
|October 27, 2009
PubMed

Insights

The MTHFR c.1298A>C gene variant may protect against multiple sclerosis (MS). Specifically, homozygosity for the A allele appears to reduce MS incidence, warranting further investigation into its protective mechanisms.

Area of Science:

  • Genetics
  • Neuroimmunology
  • Autoimmune Diseases

Background:

  • Multiple sclerosis (MS) is a central nervous system inflammatory demyelinating autoimmune disease.
  • Genetic factors are implicated in MS etiology, but specific associations require further elucidation.

Purpose of the Study:

  • To investigate the association of two MTHFR gene missense variants (c.677C>T and c.1298A>C) with multiple sclerosis risk.
  • To determine if these MTHFR variants influence the incidence of clinically definite relapsing-remitting MS.

Main Methods:

  • Case-control study comparing 138 MS patients with 138 healthy controls.
  • Genotyping of MTHFR c.677C>T (p.A222V) and c.1298A>C (p.E429A) polymorphisms.
  • Statistical analysis using Pearson's chi-squared test to compare genotype frequencies.

Main Results:

  • No significant difference in MTHFR c.677C>T polymorphism frequency between MS patients and controls.
  • Significant difference in MTHFR c.1298A>C genotype frequencies between MS patients and controls (p=0.004).
  • Homozygosity for the MTHFR c.1298A>C A allele was less frequent in MS patients, suggesting a potential protective effect.

Conclusions:

  • The MTHFR c.1298A>C polymorphism, specifically the AA genotype, may be associated with a reduced risk of developing multiple sclerosis.
  • Further research in independent cohorts is needed to confirm these findings and explore the underlying biochemical mechanisms.
  • Identifying genetic factors like MTHFR variants could offer new insights into MS pathophysiology and potential therapeutic targets.

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...